# TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

> **NCT00203320** · PHASE1 · COMPLETED · sponsor: **Tobinick, Edward Lewis, M.D.** · enrollment: 30 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** etanercept given by perispinal administration

## Key facts

- **NCT ID:** NCT00203320
- **Lead sponsor:** Tobinick, Edward Lewis, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2006-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203320, "TNF-Alpha Inhibition for Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00203320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*